Multiple myeloma is a plasma cell malignancy and remains one of the most treatment-intensive segments of hematologic oncology. The disease is characterized by recurrent relapse, clonal evolution, bone marrow involvement, immunosuppression, renal complications, anemia, and bone disease, creating sustained demand for effective multiple myeloma drugs across newly diagnosed, relapsed, and refractory settings.

The market is being reshaped by proteasome inhibitors, immunomodulatory agents, corticosteroid combinations, anti-CD38 monoclonal antibodies, selective nuclear export inhibitors, BCMA-targeted therapies, CAR-T cell therapies, bispecific antibodies, and emerging cereblon E3 ligase modulators. Clinical practice continues to move toward earlier use of combination regimens, measurable residual disease assessment, and personalized sequencing based on patient fitness, cytogenetic risk, prior exposure, and treatment response.

According to widely used oncology references and public health sources such as WHO/IARC GLOBOCAN, the American Cancer Society, NCCN, ESMO, FDA, and EMA, multiple myeloma incidence rises sharply with age and remains a major cause of hematologic cancer mortality despite substantial therapeutic advances. This creates a durable need for innovation that improves depth of response, prolongs progression-free survival, reduces treatment burden, and expands access to advanced therapies.

Transformative Shifts in the Multiple Myeloma Drug Landscape

The multiple myeloma drug landscape is undergoing a structural shift from traditional chemotherapy-centered care to multi-mechanism, immune-based, and biomarker-informed treatment strategies. Anti-CD38 antibodies have become foundational in many frontline and relapse regimens, while BCMA-directed CAR-T therapies and bispecific antibodies are redefining expectations in heavily pretreated relapsed or refractory multiple myeloma.

A second transformative shift is the movement of high-efficacy therapies into earlier lines of treatment. Regulatory decisions and clinical trial results increasingly support the use of quadruplet regimens, maintenance optimization, and risk-adapted approaches that aim to deepen response and extend remission. At the same time, clinicians must manage cumulative toxicities such as cytopenias, infections, neuropathy, thromboembolic risk, and cytokine release syndrome.

Commercial strategy is also changing. Manufacturers are investing in subcutaneous formulations, outpatient administration models, companion diagnostics, real-world evidence generation, and payer-facing value dossiers. As more mechanisms enter the market, competitive differentiation depends on survival outcomes, safety, convenience, manufacturability, access programs, and evidence in high-risk populations.

Cumulative Impact of Artificial Intelligence on Multiple Myeloma Drugs

Artificial intelligence is becoming an enabling layer across multiple myeloma drug discovery, development, diagnosis, and treatment optimization. In research, AI-supported target discovery, protein modeling, screening prioritization, and translational analytics are helping identify novel antigens, resistance pathways, and rational combination strategies. These tools are particularly relevant in a disease marked by genomic heterogeneity and treatment-induced clonal evolution.

In clinical development, AI can improve trial design by supporting patient stratification, site selection, eligibility matching, synthetic control exploration, and real-time safety monitoring. For multiple myeloma, where endpoints such as progression-free survival, overall survival, minimal residual disease negativity, and quality of life are central, advanced analytics can strengthen evidence generation when used with validated datasets and transparent governance.

In care delivery, AI-enabled decision support may help interpret laboratory trends, imaging, cytogenetics, sequencing history, and adverse event risk. However, adoption depends on clinical validation, interoperability, bias mitigation, data privacy, and regulatory oversight. The strongest near-term impact is expected where AI augments clinician decision-making rather than replacing specialist judgment.

Key Regional Insights Across the Multiple Myeloma Drug Market

North America remains a leading region for multiple myeloma drug innovation due to high oncology spending, rapid uptake of FDA-approved therapies, extensive clinical trial infrastructure, and strong specialist networks. The United States anchors regional demand through broad adoption of anti-CD38 antibodies, CAR-T therapy, bispecific antibodies, and evidence-based guidelines, while Canada emphasizes health technology assessment and publicly funded access pathways. Across the region, treatment standards are strongly influenced by regulatory review, guideline updates, transplant eligibility assessment, specialty pharmacy distribution, and real-world safety monitoring.

Europe is defined by EMA approvals, national reimbursement negotiations, and guideline-driven adoption across major markets. The European Union supports harmonized regulatory oversight, but access timelines vary by country, particularly for high-cost cell and gene therapies. The United Kingdom, Germany, France, Italy, and Spain remain important markets due to specialized hematology centers, formal health technology assessment systems, and real-world evidence programs that evaluate clinical benefit, added therapeutic value, and budget impact.

Asia-Pacific is expanding as China, Japan, South Korea, Australia, and India increase access to novel myeloma drugs, local clinical trials, and domestic biopharmaceutical development. China's regulatory modernization and growing oncology infrastructure are improving availability of innovative therapies, while Japan's aging population and advanced hematology practice support strong clinical demand. Latin America shows growing adoption in Brazil and Mexico but continues to face reimbursement, diagnostic capacity, and specialist access constraints. The Middle East, led by GCC health systems, is investing in oncology centers, medical tourism, and advanced therapeutics, while Africa remains underpenetrated due to limited specialist access, late diagnosis, constrained reimbursement, and uneven availability of advanced diagnostics.

Key Group Insights for Multiple Myeloma Drug Commercial Strategy

The G7 remains central to the multiple myeloma drug market because it includes major innovation, reimbursement, and clinical guideline economies such as the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom. These countries shape global standards through regulatory decisions, pivotal trials, health technology assessments, transplant center networks, and adoption of advanced therapies including CAR-T cells and bispecific antibodies.

The European Union provides a structured regulatory and pharmacovigilance environment through EMA oversight, while individual member states determine pricing and reimbursement. This creates a market where clinical value must be matched with cost-effectiveness evidence, real-world outcomes, budget impact management, and equitable access strategies. NATO countries collectively include advanced healthcare systems with strong demand for secure pharmaceutical supply chains, resilient medicine access, and coordinated preparedness for critical therapies, including oncology biologics and cell therapies.

BRICS economies are increasingly important due to large patient populations, expanding cancer infrastructure, and growing domestic pharmaceutical capabilities in China, India, Brazil, Russia, and South Africa. China and India are particularly relevant for clinical development, manufacturing capacity, biosimilars, and broader access initiatives, while Brazil and South Africa highlight the need for public-sector affordability strategies. ASEAN markets are improving oncology access through public-private investment, regional procurement strategies, and expanding specialist care, although availability of premium biologics remains uneven across member countries. GCC countries are prioritizing specialty care modernization, advanced hospital infrastructure, international clinical collaborations, and access to innovative oncology drugs for high-complexity hematologic malignancies.

Key Country Insights in the Multiple Myeloma Drug Market

The United States is the most influential country market for multiple myeloma drugs because of rapid FDA approvals, high clinical trial activity, strong specialty pharmacy networks, advanced transplant and cellular therapy capacity, and early adoption of novel mechanisms. Canada follows a more centralized access model, with reimbursement decisions shaped by clinical benefit, cost-effectiveness, pan-Canadian review processes, and provincial implementation. Mexico and Brazil are important Latin American markets where demand is rising, but access depends on public coverage, private insurance, oncology center concentration, and availability of specialized hematology services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent major demand centers with established hematology networks and formal health technology assessment processes. Germany often provides comparatively early post-approval access within Europe, while France, Italy, and Spain emphasize negotiated reimbursement, evidence of added therapeutic value, and managed access considerations. The United Kingdom combines guideline-driven care with cost-effectiveness assessment and specialized cancer networks. Russia maintains domestic oncology demand but faces access variability linked to procurement dynamics, local availability, and geopolitical constraints.

In Asia-Pacific, China is expanding through domestic innovation, regulatory reform, broader oncology insurance coverage, and rising clinical trial participation. Japan remains a high-value market with advanced clinical practice, strong safety monitoring, and an aging population that increases the clinical relevance of tolerable long-term regimens. India has a substantial patient base and strong generics and biosimilars capabilities, though affordability remains a barrier for premium therapies and advanced cell-based treatment. Australia and South Korea show high standards of oncology care, reimbursement scrutiny, active clinical research ecosystems, and strong interest in innovative immune-based treatments for relapsed or refractory multiple myeloma.

Actionable Recommendations for Multiple Myeloma Drug Leaders

Industry leaders should prioritize differentiated clinical evidence that demonstrates meaningful improvements in progression-free survival, overall survival, minimal residual disease negativity, safety, convenience, and patient-reported outcomes. As the treatment landscape becomes crowded, products must show value in defined patient groups such as high-risk cytogenetics, frail older adults, renal impairment, prior anti-CD38 exposure, triple-class refractory disease, and patients requiring outpatient-friendly treatment options.

Organizations should invest in access strategies early, including health economic models, real-world evidence, outcomes-based contracting, and patient support programs. For advanced therapies, manufacturing reliability, vein-to-vein time, outpatient administration readiness, referral pathway development, infection prevention, and toxicity management protocols are critical competitive factors.

Partnerships with academic centers, diagnostic developers, AI platforms, contract manufacturers, and regional distributors can accelerate trial execution and market penetration. Leaders should also strengthen pharmacovigilance, equitable access planning, supply chain resilience, and lifecycle management through new formulations, rational combinations, label expansion, and earlier-line indications.

Research Methodology for the Multiple Myeloma Drug Analysis

This executive summary is built using secondary research principles aligned with pharmaceutical market intelligence best practices. Sources considered include public regulatory databases, clinical guideline organizations, peer-reviewed oncology literature, cancer epidemiology resources, clinical trial registries, health technology assessment frameworks, and publicly available policy documents.

The analysis emphasizes verified and widely recognized evidence from organizations such as the FDA, EMA, WHO/IARC, NCCN, ESMO, national cancer agencies, and published clinical trial data. Market interpretation focuses on therapy class evolution, regional access dynamics, patient segmentation, regulatory activity, clinical development trends, and adoption drivers rather than unsupported numerical forecasting.

Insights were synthesized through triangulation of epidemiology, treatment guidelines, regulatory approvals, clinical development trends, reimbursement considerations, safety requirements, and care delivery constraints. The methodology favors data-backed interpretation, transparent assumptions, and practical relevance for pharmaceutical manufacturers, investors, payers, providers, and commercial strategy teams.

Conclusion: Future Outlook for Multiple Myeloma Drugs

The multiple myeloma drug market is advancing rapidly as immunotherapy, targeted therapy, and precision treatment strategies reshape standards of care. While the disease remains largely incurable for many patients, deeper responses and longer remission periods are increasingly achievable through combination regimens, maintenance strategies, measurable residual disease assessment, and novel immune-directed therapies.

Future success will depend on clinical differentiation, earlier-line expansion, access to advanced therapies, real-world outcomes, manufacturing readiness, and the ability to serve diverse patient populations across mature and emerging markets. Organizations that combine scientific innovation with evidence-based access planning, AI-enabled development, supply chain resilience, and patient-centered delivery models will be best positioned to lead the next phase of multiple myeloma treatment.

Product Code: MRR-036C5CF3A894

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Multiple Myeloma Drug Market, by Drug Class

7.1. Histone Deacetylase Inhibitors
7.2. Immunomodulatory Agents
- 7.2.1. Lenalidomide
- 7.2.2. Pomalidomide
- 7.2.3. Thalidomide
7.3. Monoclonal Antibodies
- 7.3.1. Daratumumab
- 7.3.2. Elotuzumab
- 7.3.3. Isatuximab
7.4. Proteasome Inhibitors
- 7.4.1. Bortezomib
- 7.4.2. Carfilzomib
- 7.4.3. Ixazomib

8. Multiple Myeloma Drug Market, by Line Of Therapy

8.1. First Line
8.2. Second Line
8.3. Third And Beyond

9. Multiple Myeloma Drug Market, by Treatment Regimen

9.1. Combination Therapy
- 9.1.1. Doublet Regimen
- 9.1.2. Quadruplet Regimen
- 9.1.3. Triplet Regimen
9.2. Monotherapy

10. Multiple Myeloma Drug Market, by Route Of Administration

10.1. Intravenous
10.2. Oral
10.3. Subcutaneous

11. Multiple Myeloma Drug Market, by Patient Age

11.1. Sixty And Above
11.2. Under Sixty

12. Multiple Myeloma Drug Market, by Line of Treatment

12.1. First-Line Therapy
12.2. Second-Line Therapy
12.3. Third-Line and Beyond

13. Multiple Myeloma Drug Market, by Patient Type

13.1. Newly Diagnosed Patients
13.2. Relapsed Patients
13.3. Refractory Patients

14. Multiple Myeloma Drug Market, by End-User

14.1. Hospitals
14.2. Specialty Clinics
14.3. Cancer Research Centers

15. Multiple Myeloma Drug Market, by Region

15.1. Asia-Pacific
15.2. North America
15.3. Latin America
15.4. Europe
15.5. Middle East
15.6. Africa

16. Multiple Myeloma Drug Market, by Group

16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO

17. Multiple Myeloma Drug Market, by Country

17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
- 18.1.1. Concentration Ratio (CR)
- 18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025

19. Company Profiles

19.1. AbbVie Inc.
19.2. Adaptive Biotechnologies Corporation
19.3. Amgen Inc.
19.4. BeiGene, Ltd.
19.5. Bristol-Myers Squibb Company
19.6. Celgene Corporation
19.7. Cellectis S.A.
19.8. Daiichi Sankyo Company, Limited
19.9. Gilead Sciences, Inc.
19.10. GlaxoSmithKline plc
19.11. Ichnos Glenmark Innovation
19.12. Johnson & Johnson Services, Inc.
19.13. Karyopharm Therapeutics Inc.
19.14. Legend Biotech Corporation
19.15. Merck & Co., Inc.
19.16. MorphoSys AG
19.17. Novartis AG
19.18. Oncopeptides AB
19.19. Pfizer Inc.
19.20. PharmaMar, S.A.
19.21. Regeneron Pharmaceuticals, Inc.
19.22. Sanofi
19.23. Takeda Pharmaceutical Company Limited
19.24. Teva Pharmaceutical Industries Ltd.

Product Code: MRR-036C5CF3A894

LIST OF FIGURES

FIGURE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

TABLE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL LENALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL LENALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL LENALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL POMALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL POMALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL POMALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL THALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL THALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL THALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DARATUMUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DARATUMUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DARATUMUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ELOTUZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ELOTUZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ELOTUZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ISATUXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ISATUXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ISATUXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BORTEZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BORTEZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BORTEZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CARFILZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CARFILZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CARFILZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IXAZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IXAZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IXAZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL THIRD AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL THIRD AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL THIRD AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL UNDER SIXTY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL UNDER SIXTY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL UNDER SIXTY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 155. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 156. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 158. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 159. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 161. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 162. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 163. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 165. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 166. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 167. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 181. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 182. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 183. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 184. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 185. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 186. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 187. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 188. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 189. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 191. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 192. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 193. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 198. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 199. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 200. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 201. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 202. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 203. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 205. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 206. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 207. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 208. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 211. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 212. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 213. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 214. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 215. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 216. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 218. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 219. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 220. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 234. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 235. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 236. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 237. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 238. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 239. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 240. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 241. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 242. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 244. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 245. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 246. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 247. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 248. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 249. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 250. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 251. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 252. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 253. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 254. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 255. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 257. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 258. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 259. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 260. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 261. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 262. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 263. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 264. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 265. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 266. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 267. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 268. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 269. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 270. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 271. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 272. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 273. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 276. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 287. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 288. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 289. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 290. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 291. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 292. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 293. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 294. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 295. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 296. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 297. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 298. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 299. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 300. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 301. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 302. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 303. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 304. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 305. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 306. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 307. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 308. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 309. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 310. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 311. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 312. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 313. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 314. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 315. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 316. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 317. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 318. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 319. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 320. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 321. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 322. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 323. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 324. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 325. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 330. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 331. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 332. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 333. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 334. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 339. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 340. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 341. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 342. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 343. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 344. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 345. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 346. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 347. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 348. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 349. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 350. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 351. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 352. FRAN

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION